Conference Coverage: EHA 2022 – Focus on Leukemia and MDS
Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making regarding leukemia
June 11, 2022
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty Members
Dan Pollyea, MD
University of Colorado Cancer Center, Aurora, CO, USA
Guillermo Garcia-Manero, MD
MD Anderson Cancer Center, Houston, TX, USA
Naval Daver, MD
MD Anderson Cancer Center, Houston, TX, USA
Harry P. Erba, MD, PhD
Duke University School of Medicine, Durham, NC, USA
Alexander E. Perl, MD
Abramson Cancer Center, Penn Medicine, Philadelphia, PA, USA
Eytan M. Stein, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Advances in AML: Newly Diagnosed – AML With Mutations
- Advances in AML: Newly Diagnosed – AML in Older and/or Unfit Patients
- Advances in AML: Newly Diagnosed – Other
- Advances in AML: Relapsed/Refractory
- New Developments in MDS
